Biomimetic Nanoerythrosome‐Coated Aptamer–DNA Tetrahedron/Maytansine Conjugates: pH‐Responsive and Targeted Cytotoxicity for HER2‐Positive Breast Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Advanced Materials"
DOI: 10.1002/adma.202109609
Abstract: DNA materials have emerged as potential nanocarriers for targeted cancer therapy to precisely deliver cargos with specific purposes. The short half‐life and low bioavailability of DNA materials due to their interception by the reticuloendothelial system… read more here.
Keywords: dna; her2 positive; drug; cancer ... See more keywords
Prognostic factors and survival prediction in HER2-positive breast cancer with bone metastases: A retrospective cohort study.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer medicine"
DOI: 10.1002/cam4.4326
Abstract: BACKGROUND Bone is the most common metastatic site of breast cancer. The developmental pattern of bone metastasis differs in different molecular subtypes. The prognostic factors of HER2-positive breast cancer with bone metastases require further investigation.… read more here.
Keywords: bone metastases; her2 positive; prognostic factors; breast cancer ... See more keywords
Genetic and immune microenvironment characterization of HER2‐positive gastric cancer: Their association with response to trastuzumab‐based treatment
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5769
Abstract: We aimed to determine the molecular and immune microenvironment characteristics of HER2‐positive gastric cancer (GC) related to the patient's response to first‐line trastuzumab‐based treatment. read more here.
Keywords: positive gastric; immune microenvironment; trastuzumab based; gastric cancer ... See more keywords
Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.5893
Abstract: The antibody-drug conjugate trastuzumab emtansine (T-DM1) is approved for human epidermal growth factor receptor 2 (HER2/ERBB2)-positive breast cancer. We aimed to study tumor HER2 expression and its effects on T-DM1 responses in patients with HER2-positive… read more here.
Keywords: cancer; patients her2; urothelial bladder; her2 positive ... See more keywords
Chk1 activation attenuates sensitivity of lapatinib in HER2‐positive gastric cancer
Sign Up to like & getrecommendations! Published in 2018 at "Cell Biology International"
DOI: 10.1002/cbin.10922
Abstract: The ATM and Rad3‐related (ATR)/checkpoint kinase 1 (Chk1) pathway plays a pivotal role in DNA damage sensor and modulating homologous recombination. Recently, emerging evidence demonstrated that Chk1 phosphorylation was associated with chemotherapy and radiotherapy resistance.… read more here.
Keywords: chk1; positive gastric; her2 positive; gastric cancer ... See more keywords
Porphyrin modified trastuzumab improves efficacy of HER2 targeted photodynamic therapy of gastric cancer
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Cancer"
DOI: 10.1002/ijc.30844
Abstract: Gastric cancer (GC) is the 3rd deadliest cancer worldwide, due to limited treatment options and late diagnosis. Human epidermal growth factor receptor‐2 (HER2) is overexpressed in ∼20% of GC cases and anti‐HER2 antibody trastuzumab in… read more here.
Keywords: therapy; her2 positive; gastric cancer; trast porph ... See more keywords
The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.
Sign Up to like & getrecommendations! Published in 2022 at "International journal of cancer"
DOI: 10.1002/ijc.34024
Abstract: We investigated the effect of trastuzumab on cardiac function in a real-world historic cohort of patients with HER2-positive metastatic breast cancer (MBC) with reduced baseline left ventricular ejection fraction (LVEF). Thirty-seven patients with HER2-positive MBC… read more here.
Keywords: severe cardiotoxicity; patients her2; cancer; her2 positive ... See more keywords
Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-019-03852-z
Abstract: PurposeThe phase III MARIANNE study investigated single-agent trastuzumab emtansine (T-DM1) and combination T-DM1 plus pertuzumab as the first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). Pharmacokinetic properties of T-DM1… read more here.
Keywords: pertuzumab; her2 positive; dm1; breast cancer ... See more keywords
Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-019-03871-w
Abstract: PurposeTo characterize the pharmacokinetics (PK) of pertuzumab and trastuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer in the randomized, double-blind, phase III JACOB study (NCT01774786), and to evaluate the appropriateness of the… read more here.
Keywords: pertuzumab trastuzumab; patients her2; her2 positive; pertuzumab ... See more keywords
Trastuzumab and survival of patients with metastatic breast cancer
Sign Up to like & getrecommendations! Published in 2017 at "Archives of Gynecology and Obstetrics"
DOI: 10.1007/s00404-017-4421-x
Abstract: IntroductionPrognosis of Her2-positive breast cancer has changed since the introduction of trastuzumab for treatment in metastatic and early breast cancer. It was described to be even better compared to prognosis of Her2-negative metastatic breast cancer.… read more here.
Keywords: her2 positive; trastuzumab; breast cancer; metastatic breast ... See more keywords
Trastuzumab treatment of patients with early, HER2-positive breast cancer in 17 certified German breast cancer centers
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-021-03651-1
Abstract: Since 2008, guidelines recommend that patients with HER2-positive early breast cancer (BC) should receive adjuvant chemotherapy in combination with trastuzumab in Germany. However, recent studies highlight that a substantial share of patients do not receive… read more here.
Keywords: recommendation; her2 positive; breast cancer; cancer ... See more keywords